Lantern Pharma (LTRN) EBITDA (2020 - 2026)

Lantern Pharma (LTRN) has reported EBITDA for 7 consecutive years, with -$3.5 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, EBITDA rose 24.59% year-over-year to -$3.5 million; the trailing twelve-month figure through Jun 2026 stood at -$15.5 million (up 24.56% YoY), and the FY2025 full-year result was -$18.0 million, up 19.08% from the prior year.
• EBITDA eased to -$3.5 million in Q2 2026 per LTRN's latest filing, from -$3.4 million in the prior quarter.
• Across five years, EBITDA topped out at -$2.1 million in Q3 2022 and bottomed at -$5.9 million in Q4 2024.
• Historically, EBITDA has averaged -$4.4 million across 5 years, with a median of -$4.4 million in 2022.
• The widest YoY moves for EBITDA: up 48.29% in 2022, down 77.28% in 2022.
• Over 5 years, EBITDA stood at -$3.8 million in 2022, then declined by 27.47% to -$4.9 million in 2023, then fell by 20.89% to -$5.9 million in 2024, then gained by 28.72% to -$4.2 million in 2025, then grew by 16.53% to -$3.5 million in 2026.
• According to Business Quant data, EBITDA over the past three periods registered -$3.5 million, -$3.4 million, and -$4.2 million for Q2 2026, Q1 2026, and Q4 2025 respectively.